AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 21829907
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral group therapy combined with pharmacotherapy
Trial: 16909131
Drug: sc‐IL‐2, sc‐IFN‐alpha2a,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sc‐IL‐2, sc‐IFN‐alpha2a, po‐13cRA + inhaled‐IL‐2 (Arm B)
Trial: 11302007
Drug: 10 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 g fish powder
Trial: 11302007
Drug: Placebo (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (20 tablets/day)
Trial: 25695403
Drug: MK-7123 50
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-7123 50 mg
Trial: 24179013
Drug: Antioxidative therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antioxidative therapy (N-acetyl cysteine or MP865)
Trial: 21931024
Drug: Early discharge
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early discharge to receive identical antibiotic treatment at home
Trial: 21931024
Drug: Continued inpatient
RxNorm normalized name: Impatiens irvingii whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued inpatient antibiotic therapy
Trial: 16879461
Drug: Bupivacaine 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 7.5 mg alone
Trial: 16879461
Drug: Bupivacaine 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 7.5 mg with 10 microg of fentanyl
Trial: 14753029
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg nimesulid bd.
Trial: 14753029
Drug: 275 mg
RxNorm normalized name: kava root 275 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 275 mg naproxen bd.
Trial: 10067689
Drug: EZ-M vaccine
RxNorm normalized name: m-phenylenediamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EZ-M vaccine
Trial: 1975045
Drug: Good adherence
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Good adherence (taking > 75% of prescribed medication)
Trial: 7029004
Drug: Glucose/electrolyte solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucose/electrolyte solution
Trial: 7029004
Drug: Sugar/salt solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar/salt solution
Trial: 30961658
Drug: Sodium benzoate
RxNorm normalized name: Sodium Benzoate
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium benzoate as an adjunctive treatment
Trial: 28535237
Drug: Ferric carboxymaltose
RxNorm normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ferric carboxymaltose (1-time or 2-time injection of 500 mg or 1000 mg according to body weight)
Trial: 9588731
Drug: Sulfasalazine (SSZ)
RxNorm normalized name: Sulfasalazine
DrugBank: Sulfasalazine (DB00795)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sulfasalazine (SSZ) 50 mg/kg/day (maximum 2,000 mg/day)
Trial: 2052798
Drug: hCG vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hCG vaccine
Trial: 29110567
Drug: Ibuprofen 200
RxNorm normalized name: ibuprofen 200 MG
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Ibuprofen 200 mg plaster
Trial: 15717881
Drug: Lifestyle intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lifestyle intervention (L)
Trial: 16555056
Drug: Insulin treatment
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin treatment (I)
Trial: 16555056
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment (L+I)
Trial: 8728123
Drug: 10 weeks
RxNorm normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 weeks of moderate dose (30 mg/d) beta‐carotene
Trial: 6136286
Drug: Diisopropyl phenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diisopropyl phenol 2 mg kg‐1 i.v. bolus injection
Trial: 6136286
Drug: Diisopropyl phenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diisopropyl phenol infusion (150 micrograms kg‐1 min‐1 for 30 min and 75 micrograms kg‐1 min‐1 thereafter)
Trial: 6136286
Drug: Diisopropyl phenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diisopropyl phenol infusion
Trial: 25068560
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care plus placebo ultrasound treatment (PUT)
Trial: 19596934
Drug: Amitriptyline (target
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (target dose, 100 mg daily)
Trial: 12920408
Drug: Clozapine 100
RxNorm normalized name: clozapine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine 100 mg/d
Trial: 12920408
Drug: Clozapine 300
RxNorm normalized name: clozapine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine 300 mg/d
Trial: 12920408
Drug: Clozapine 600
RxNorm normalized name: clozapine 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clozapine 600 mg/d
Trial: 14694498
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Creatine monohydrate (CrM) supplementation (5 g daily)
Trial: 9825105
Drug: Ofloxacin (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ofloxacin (400 mg orally once a day or 200 mg intravenously twice a day for 2‐4 days followed by oral use for 6‐8 days)
Trial: 7621388
Drug: Clomipramine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clomipramine and behaviour therapy
Trial: 25444803
Drug: MF59-adjuvanted vaccine
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59-adjuvanted vaccine (3.75 μg antigen with half a standard dose of MF59)
Trial: 25444803
Drug: MF59-adjuvanted vaccine
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59-adjuvanted vaccine (7.5 μg antigen with a full dose of MF59)
Trial: 25444803
Drug: Non-adjuvanted vaccine
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-adjuvanted vaccine (15 μg formulation)
Trial: 25444803
Drug: MF59-adjuvanted vaccine
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF59-adjuvanted vaccine (3.75 μg antigen)
Trial: 25444803
Drug: All A/H1N1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All A/H1N1 vaccine formulations
Trial: 22063370
Drug: Morphine (20mg)
RxNorm normalized name: morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine (20mg)
Trial: 8287640
Drug: Mild hypoglycaemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild hypoglycaemia (3.3 mmol/l)
Trial: 8287640
Drug: Mild hypoglycaemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild hypoglycaemia (3.7 mmol/l)
Trial: 8287640
Drug: Moderate hypoglycaemia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate hypoglycaemia (2.5 mmol/l) after mild hypoglycaemia
Trial: 8287640
Drug: Control (blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (blood glucose maintained at 4.5 mmol/l)
Trial: 25110439
Drug: Cholecystokinin (CCK)
RxNorm normalized name: cholecystokinin
DrugBank: Cholecystokinin (DB08862)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecystokinin (CCK) administered at a dose of 3 ng/kg per min for 10 min intravenously before ESWL
Trial: 18809608
Drug: Vaccination with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccination with the six-peptide melanoma vaccine
Trial: 16138265
Drug: Glimepiride (1-6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride (1-6 mg)
Trial: 12374234
Drug: Nitrates (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrates (0.1 mg/kg)
Trial: 7558945
Drug: Chemoradiotherapy (two
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiotherapy (two cycles of cisplatin 100 mg/m2 Day 1, 5-fluorouracil 1000 mg/m2 24-h infusion Days 2, 3, and 4 before radical radiotherapy, and four cycles of postradiotherapy chemotherapy)
Trial: 855810
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg of lysine with 260 mg of tryptophan
Trial: 855810
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg of lysine with 390 mg of tryptophan
Trial: 855810
Drug: 900 mg
RxNorm normalized name: diosmin 900 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 900 mg of lysine with 520 mg of tryptophan
Trial: 855810
Drug: 1800 mg
RxNorm normalized name: glycerin 1800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1800 mg of lysine with 260 mg of tryptophan
Trial: 855810
Drug: 1800 mg
RxNorm normalized name: glycerin 1800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1800 mg of lysine with 390 mg of tryptophan
Trial: 855810
Drug: 1800 mg
RxNorm normalized name: glycerin 1800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1800 mg of lysine with 520 mg of tryptophan
Trial: 25467617
Drug: Metformin treated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin treated groups
Trial: 23563442
Drug: Daily wear
RxNorm normalized name: ZINC OXIDE 22.7 g in 100 g TOPICAL LOTION [ETHICAL ZINC DAILY WEAR LIGHT SUNSCREEN SPF-50]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily wear (DW)
Trial: 1560429
Drug: One antihypertensive
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One antihypertensive medication
Trial: 25012072
Drug: Single psycho‐oncological
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single psycho‐oncological therapy session
Trial: 22450428
Drug: Aliskiren (150-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren (150-300 mg/daily)
Trial: 22450428
Drug: Ramipril (5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramipril (5-10 mg/daily)
Trial: 17139035
Drug: Olanzapine monotherapy
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olanzapine monotherapy for 1 year
Trial: 17139035
Drug: Lithium monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lithium monotherapy for 1 year
Trial: 10958077
Drug: Oral cocaine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cocaine (100 mg, p.o.)
Trial: 10958077
Drug: Oral cocaine
RxNorm normalized name: Cocaine
DrugBank: Cocaine (DB00907)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral cocaine (0 mg, 25 mg, 50 mg, 100 mg, 0 mg)
Trial: 9078828
Drug: Early indomethacin
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early indomethacin (0.2 mg/kg intravenously at 12 postnatal hours and every 24 h for two more doses)
Trial: 29595671
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine infusion (2.0 mg/kg bolus, 3.0 mg/kg/h infusion)
Trial: 26551637
Drug: Allogeneic hematopoietic
RxNorm normalized name: allogeneic processed thymus tissue Drug Implant [Rethymic]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allogeneic hematopoietic cell transplantation (alloHCT) as consolidation treatment in first remission for HR(FLT3‐ITD) AML
Trial: 26551637
Drug: Consolidation chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation chemotherapy for HR(FLT3‐ITD) AML
Trial: 25042700
Drug: Multi‐modality therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi‐modality therapy (complete cytoreductive surgery (CRS), hyperthermic intraperitoneal chemotherapy (HIPEC), and systemic FOLFOXIRI)
Trial: 25042700
Drug: Systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic chemotherapy (FOLFOXIRI alone)
Trial: 22500909
Drug: Intrathecal magnesium
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal magnesium (0.5 mL magnesium 10% combined with bupivacaine 15 mg)
Trial: 22500909
Drug: Intrathecal fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intrathecal fentanyl (0.5 mL fentanyl combined with bupivacaine 15 mg)
Trial: 22500909
Drug: Control (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0.5 mL distilled water combined with bupivacaine 15 mg)
Trial: 20595645
Drug: Strawberry beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strawberry beverage (Str; containing 10 g freeze-dried fruit)
Trial: 14659354
Drug: Epirubicin 60-90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 60-90 mg/m2 on day 1 and vinorelbine 15-25 mg/m2 on days 1 and 8, repeated every 3 weeks
Trial: 14659354
Drug: Epirubicin 60-90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin 60-90 mg/m2 on day 1 and vinorelbine 15-25 mg/m2 on days 1 and 8
Trial: 10870037
Drug: Glucagon (GLU;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucagon (GLU; 0.017 mg/kg i.m.)
Trial: 10870037
Drug: Glucagon (GLU;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucagon (GLU; 0.017 mg/kg i.m.) + hCRH (2.0 µg/kg i.v.)
Trial: 10870037
Drug: Glucagon (GLU;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glucagon (GLU; 0.017 mg/kg i.m.) + AVP (0.17 U/kg i.m.)
Trial: 9195148
Drug: Azelastine (0.56
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine (0.56 mg bid)
Trial: 9195148
Drug: Beclomethasone (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone (0.2 mg bid)
Trial: 9114912
Drug: Dilevalol 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dilevalol 800 mg
Trial: 3984975
Drug: Naproxen sodium
RxNorm normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naproxen sodium therapy
Trial: 30394834
Drug: Tightly controlled
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tightly controlled renoprotective protocol including regular clinical evaluations, blood pressure management, and glucocorticoid dose reduction if indicated.
Trial: 24164309
Drug: Aloe vera
RxNorm normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aloe vera gel (0.5% w/w), applied four times a day for 5 days
Trial: 24164309
Drug: Myrrh gel
RxNorm normalized name: Myrrh
DrugBank: Myrrh (DB11605)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myrrh gel (0.5% w/w), applied four times a day for 5 days
Trial: 24164309
Drug: Plain mucoadhesive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plain mucoadhesive gel (placebo), applied four times a day for 5 days
Trial: 22172430
Drug: 40 infusions
RxNorm normalized name: nitroglycerin
DrugBank: Nitroglycerin (DB00727)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 infusions of a multicomponent disodium EDTA chelation solution
Trial: 22172430
Drug: Oral, high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, high-dose multivitamin and mineral supplement
Trial: 20797891
Drug: Preoperative radiotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative radiotherapy (preop-RT) with chemotherapy (CT)
Trial: 20797891
Drug: Preoperative radiotherapy
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative radiotherapy (preop-RT) without chemotherapy (Control)
Trial: 18402597
Drug: Regular doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular doses of CBM588
Trial: 18402597
Drug: Double doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double doses of CBM588
Trial: 18402597
Drug: Regular doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular doses of CBM588 (Group B)
Trial: 18402597
Drug: Double doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double doses of CBM588 (Group C)
Trial: 8646946
Drug: Octreotide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (100 micrograms bolus injection)
Trial: 8646946
Drug: Octreotide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (10 micrograms bolus injection)
Trial: 8646946
Drug: Octreotide (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide (250 micrograms/hour infusion)
Trial: 1655867
Drug: Intraarterial Adriamycin
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraarterial Adriamycin (60 mg/m2) with lipiodol (10 ml)
Trial: 1655867
Drug: Intraarterial Adriamycin
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraarterial Adriamycin (60 mg/m2) without lipiodol
Trial: 1655867
Drug: Intravenous Adriamycin
RxNorm normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous Adriamycin (60 mg/m2)
Trial: 6344591
Drug: Ascorbic acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ascorbic acid therapy
Trial: 31989151
Drug: roluperidone 32
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roluperidone 32 mg
Trial: 31989151
Drug: roluperidone 64
RxNorm normalized name: Domperidone
DrugBank: Domperidone (DB01184)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: roluperidone 64 mg
Trial: 28074235
Drug: Chemotherapy and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy and CNS radiotherapy
Trial: 28074235
Drug: Both treated
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both treated groups (chemotherapy alone and chemotherapy with CNS radiotherapy)
Trial: 26022945
Drug: CPAP treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP treatment for 3 months
Trial: 26022945
Drug: No CPAP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No CPAP treatment for 3 months
Trial: 23143842
Drug: Co-trimoxazole 960
RxNorm normalized name: CO
DrugBank: Carbon monoxide (DB11588)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole 960 mg twice daily
Trial: 15918064
Drug: Viscoseal (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viscoseal (10 ml)
Trial: 10908002
Drug: Matrix model,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matrix model, a manualized program of intensive outpatient treatment
Trial: 8455074
Drug: Erythromycin (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (3 mg.kg-1 i.v. over 20 min)
Trial: 3778565
Drug: 60‐mg urapidil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60‐mg urapidil slow release‐capsule
Trial: 3778565
Drug: 30‐mg urapidil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30‐mg urapidil drinking ampoule (Ebrantil)
Trial: 12422059
Drug: Nortriptyline (targeted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline (targeted to 190-570 nmol/l)
Trial: 9589267
Drug: Naloxone 0.5
RxNorm normalized name: naloxone 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone 0.5 mg
Trial: 9589267
Drug: Buprenorphine 2
RxNorm normalized name: buprenorphine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buprenorphine 2 mg/naloxone 0.5 mg
Trial: 8024075
Drug: Mefloquine (1,250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mefloquine (1,250 mg divided between two doses of 750 and 500 mg six hours apart) plus doxycycline (200 mg once a day for seven days)
Trial: 8024075
Drug: Artesunate (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artesunate (300 mg total for 2.5 days; 100 mg followed by 50 mg every 12 hr for 2.5 days) plus doxycycline (200 mg once a day for seven days)
Trial: 19622463
Drug: Rituximab 375
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 375 mg/m², Cyclophosphamide 1000 mg/m², Vincristine 1.4 mg/m² (max 2 mg), Prednisone 50 mg every other day for 30 days, G-CSF on days 7-10 after each cycle
Trial: 15548216
Drug: Local anaesthetic
RxNorm normalized name: Local anaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anaesthetic cream (EMLA) applied for forearm skin anaesthesia
Trial: 15548216
Drug: Local anaesthetic
RxNorm normalized name: Local anaesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anaesthetic cream (EMLA)
Trial: 26936358
Drug: 1200 mg/d
RxNorm normalized name: Rebetron, single dose 1200 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg/d ibuprofen (IBU)
Trial: 24734285
Drug: SQ-standardized subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SQ-standardized subcutaneous immunotherapy (SCIT)
Trial: 24734285
Drug: Allergen immunotherapy
RxNorm normalized name: Allergen immunotherapy extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Allergen immunotherapy tablets (SLIT tablet)
Trial: 24734285
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (neither SCIT nor SLIT tablet)
Trial: 20110249
Drug: Cinacalcet (30‐180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cinacalcet (30‐180 mg/day) plus low‐dose active vitamin D